Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRAY Graybug Vision	$2.37 -4.6%	$2.32	$5.00 ▼ $22.12	$3.72M	1.2	2,165 shs	26,650 shs
MTNB Matinas Biopharma	$2.36 +43.0%	$0.98	$0.47 ▼ $7.91	$8.39M	1.32	439,641 shs	22.54 million shs
NBY NovaBay Pharmaceuticals	$0.62 +2.1%	$0.62	$0.44 ▼ $1.01	$3.59M	0.4	108,078 shs	212,919 shs
TMBR Timber Pharmaceuticals		$1.87	$0.32 ▼ $3.39	$1.21M	0.03	511,937 shs	26,307 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRAY Graybug Vision	-14.31%	-21.17%	+1.94%	+23.63%	-47.79%
MTNB Matinas Biopharma	+6.11%	+87.93%	+66.60%	+89.00%	+788.53%
NBY NovaBay Pharmaceuticals	+2.51%	+3.95%	-9.73%	+2.51%	+30.29%
TMBR Timber Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	1.5306 of 5 stars	0.0	5.0	0.0	0.0	3.9	0.0	0.6
NBY NovaBay Pharmaceuticals	1.6845 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.0	1.3
TMBR Timber Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRAY Graybug Vision	0.00	N/A	N/A	N/A
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	37.65% Upside
TMBR Timber Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRAY Graybug Vision	N/A	N/A	N/A	N/A	$1.67 per share	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.37	N/A	N/A	$4.25 per share	0.15
TMBR Timber Pharmaceuticals	$80K	0.00	N/A	N/A	$1.79 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRAY Graybug Vision	-$35.60M	-$24.23	N/A	N/A	N/A	N/A	-77.61%	-71.34%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
TMBR Timber Pharmaceuticals	-$19.38M	N/A	0.00	N/A	N/A	N/A	-511.45%	-180.93%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TMBR Timber Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRAY Graybug Vision	N/A	10.73	10.72
MTNB Matinas Biopharma	N/A	5.53	5.53
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
TMBR Timber Pharmaceuticals	N/A	0.50	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRAY Graybug Vision	49.94%
MTNB Matinas Biopharma	11.77%
NBY NovaBay Pharmaceuticals	23.25%
TMBR Timber Pharmaceuticals	3.62%

Insider Ownership

Company	Insider Ownership
GRAY Graybug Vision	7.94%
MTNB Matinas Biopharma	4.60%
NBY NovaBay Pharmaceuticals	0.10%
TMBR Timber Pharmaceuticals	1.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRAY Graybug Vision	27	1.57 million	20.25 million	Not Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
TMBR Timber Pharmaceuticals	9	3.43 million	3.38 million	Not Optionable

TMBR, GRAY, MTNB, and NBY Headlines

Recent News About These Companies

MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources

January 31, 2025 | nypost.comN

Timber back in Dutch squad and twin brother also called up

August 30, 2024 | reuters.com

Rare disease drug from LEO's Timber felled by failed study

August 25, 2024 | pharmaphorum.comP

Can timber construction overcome its growing pains?

May 13, 2024 | reuters.com

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

March 10, 2024 | businesswire.com

Timber Pharmaceuticals Announces Official Name Change

January 28, 2024 | msn.com

Timber Pharmaceuticals Inc (TMBRQ)

January 13, 2024 | uk.investing.com

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

November 29, 2023 | finance.yahoo.com

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

November 29, 2023 | finance.yahoo.com

Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

November 28, 2023 | tmcnet.com

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

November 28, 2023 | finance.yahoo.com

MVST, FBIO and VTVT among mid-day movers

November 21, 2023 | seekingalpha.com

Timber Pharmaceuticals files for Chapter 11 in wake of failed merger

November 17, 2023 | msn.com

Timber Pharma slips ahead of shareholder vote on merger

November 16, 2023 | msn.com

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

September 18, 2023 | finance.yahoo.com

HC Wainwright Downgrades Timber Pharmaceuticals

August 29, 2023 | 247wallst.com

HC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)

August 28, 2023 | msn.com

Timber Pharmaceuticals rockets as it agrees to a takeover

August 21, 2023 | thepharmaletter.comT

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

August 21, 2023 | benzinga.com

Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher

August 21, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMBR, GRAY, MTNB, and NBY Company Descriptions

Graybug Vision NASDAQ:GRAY

$2.37 -0.12 (-4.64%)

As of 08/13/2025

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Matinas Biopharma NYSE:MTNB

$2.36 +0.71 (+43.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.06 (+2.71%)

As of 08:00 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

NovaBay Pharmaceuticals NYSE:NBY

$0.62 +0.01 (+2.10%)

As of 03:58 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Timber Pharmaceuticals NYSE:TMBR

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time